KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Arbutus Biopharma (ABUS) Other Gross PP&E Adjustments (2016 - 2025)

Arbutus Biopharma's Other Gross PP&E Adjustments history spans 15 years, with the latest figure at $15.3 million for Q4 2024.

  • For Q4 2024, Other Gross PP&E Adjustments rose 0.65% year-over-year to $15.3 million; the TTM value through Dec 2024 reached $15.3 million, up 0.65%, while the annual FY2024 figure was $15.3 million, 0.65% up from the prior year.
  • Other Gross PP&E Adjustments for Q4 2024 was $15.3 million at Arbutus Biopharma, up from -$1.1 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $15.3 million in Q4 2024 and bottomed at -$2.7 million in Q1 2020.
  • The 5-year median for Other Gross PP&E Adjustments is -$1.6 million (2023), against an average of $2.1 million.
  • The largest YoY upside for Other Gross PP&E Adjustments was 23.83% in 2024 against a maximum downside of 0.65% in 2024.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $12.1 million in 2020, then grew by 9.24% to $13.3 million in 2021, then grew by 6.5% to $14.1 million in 2022, then increased by 7.3% to $15.2 million in 2023, then grew by 0.65% to $15.3 million in 2024.
  • Per Business Quant, the three most recent readings for ABUS's Other Gross PP&E Adjustments are $15.3 million (Q4 2024), -$1.1 million (Q3 2024), and -$1.2 million (Q2 2024).